A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent
Clinical trial NCT03768960 · COMPLETED
Trial details
- NCT number
- NCT03768960
- Sponsor
- Johnson & Johnson Private Limited
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-10
- Primary completion
- 2022-07-16
- Enrollment
- 150
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.